Companies · Listed company · 🇮🇳

Neogen Chemicals Limited

NEOGEN · NSE · ₹2,407 a share (close of 01 Oct 2026)

Available company data, source links and archived checks for Neogen Chemicals Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.

Revenue rose 34.0%; Net profit was ₹17.11 crore.

Quarter ended 2026-06-30 · consolidated · Company filing

Recorded quarterly figures

Quarter	Revenue / income	YoY	Profit	YoY	Net margin	Source
Jun 2026	Revenue: ₹250 cr	+34.0%	Net profit: ₹17 cr	+66.8%	6.8%	Company filing source
Mar 2026	Revenue: ₹247 cr	+21.6%	Net profit: ₹11 cr	+372.6%	4.6%	Company filing source
Dec 2025	Revenue: ₹220 cr	—	Net profit: ₹4 cr	—	1.7%	Company filing source
Sep 2025	Revenue: ₹209 cr	—	Net profit: ₹3 cr	—	1.6%	Company filing source
Jun 2025	Revenue: ₹187 cr	+3.8%	Net profit: ₹10 cr	-10.5%	5.5%	Company filing source
Mar 2025	Revenue: ₹203 cr	—	Net profit: ₹2 cr	—	1.2%	Company filing source

YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.

Recently checked facts

NEOGEN: consolidated net profit changed by 66.8% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.

✓ verified by recomputing archived check · 2026-09-28 exchange filing →

NEOGEN: consolidated net profit for the quarter ending 30 June 2026 was ₹17.11 crore.

✓ verified by recomputing archived check · 2026-09-28 exchange filing →

NEOGEN: consolidated revenue changed by 34.0% in the quarter ending 30 June 2026, compared with the quarter ending 2025-06-30.

✓ verified by recomputing archived check · 2026-09-28 exchange filing →

NEOGEN: consolidated revenue for the quarter ending 30 June 2026 was ₹250.29 crore.

✓ verified by recomputing archived check · 2026-09-28 exchange filing →

Who holds it — from the filings

Haridas Kanani Family Trust (Beena Haridas Kanani and Harin Haridas Kanani) 19.3%Harin Haridas Kanani 12.2%Beena Kanani Family Trust (Haridas Thakarshi Kanani and Harin Haridas Kanani) 9.6%Sbi Contra Fund 5.3%Cadamba Solutions Private Limited 4.9%register as filed 2026-09-16

Filing timeline — what the company told the exchange

Disclosure of material issue. Neogen Chemicals Limited has informed regarding Disclosure pertaining to approval by the Board of Neogen Morita New Materials Limi… 26 Sep 2026 · document
Neogen Chemicals Limited has informed the Exchange about Credit Rating- Revision.… 26 Sep 2026 · document
Neogen Chemicals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015… 25 Sep 2026 · document
Analysts/Institutional Investor Meet/Con. Call Updates. Neogen Chemicals Limited has informed the Exchange about Schedule of meet… 23 Sep 2026 · document
Press Release. Neogen Chemicals Limited has informed the Exchange regarding a press release dated September 21, 2026, titled "Neogen Chemicals raises approx INR… 21 Sep 2026 · document
Analysts/Institutional Investor Meet/Con. Call Updates. Neogen Chemicals Limited has informed the Exchange about Schedule of Analyst/Investor meeting to be held… 17 Sep 2026 · document
Neogen Chemicals Limited has informed the Exchange about General Updates… 16 Sep 2026 · document
Qualified Institutional Placement. Neogen Chemicals Limited has informed the Exchange about qualified Institutional Placement… 16 Sep 2026 · document

Follow this company without reading every document yourself.

Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.

Start free — first week on us →

India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment advice · cancel any time

Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances